Anti-inflammatory effects of high-dose IgG on TNF-α-activated human coronary artery endothelial cells

European Journal of Immunology

Volumn 42, Issue 8, 2012, Pages 2121-2131

  Matsuda, Akio ^a   Morita, Hideaki ^a,b   Unno, Hirotoshi ^a,c   Saito, Hirohisa ^a   Matsumoto, Kenji ^a   Hirao, Yutaka ^d   Munechika, Koji ^d   Abe, Jun ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Benesis Corporation   (Japan)

Author keywords

Coronary artery endothelial cells; IVIG; Kawasaki disease; TNF

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ENDOTHELIUM CELL; CYTOKINE RELEASE; DRUG MEGADOSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION;

CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INTERLEUKIN-1BETA; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; MUCOCUTANEOUS LYMPH NODE SYNDROME; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864769308     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242398     Document Type: Article

References (41)

1. Misra, N., Bayary, J., Dasgupta, S., Ephrem, A., Huyen, J. P., Delignat, S., Hassan, G. et al., Intravenous immunoglobulin and dendritic cells. Clin. Rev. Allergy Immunol. 2005. 29: 201-205.
2. Ballow, M., The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 2011. 127: 315-323.
3. Basta, M., Van Goor, F., Luccioli, S., Billings, E. M., Vortmeyer, A. O., Baranyi, L., Szebeni, J. et al., F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 2003. 9: 431-438.
4. Kazatchkine, M. D. and Kaveri, S. V., Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001. 345: 747-755.
5. Samuelsson, A., Towers, T. L. and Ravetch, J. V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001. 291: 484-486.
6. Ravetch, J. V. and Bolland, S., IgG Fc receptors. Annu. Rev. Immunol. 2001. 19: 275-290.
7. Ephrem, A., Chamat, S., Miquel, C., Fisson, S., Mouthon, L., Caligiuri, G., Delignat, S. et al., Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008. 111: 715-722.
8. Maddur, M. S., Vani, J., Hegde, P., Lacroix-Desmazes, S., Kaveri, S. V., Bayry, J., Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 2011. 127: 823-830.
9. Kawasaki, T., Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967. 16: 178-222.
10. Melish, M. E., Hicks, R. M., andLarson, E. J., Mucocutaneous lymph node syndrome in the United States. Am. J. Dis. Child. 1976. 130: 599-607.
11. Kawasaki, T., Kosaki, F., Okawa, S., Shigematsu, I., andYanagawa, H., A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974. 54: 271-276.
12. Furusho, K., Kamiya, T., Nakano, H., Kiyosawa, N., Shinomiya, K., Hayashidera, T., Tamura, T. et al., High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984. 2: 1055-1058.
13. Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P. et al., The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 1986. 315: 341-347.
14. Newburger, J. W., Takahashi, M., Beiser, A. S., Burns, J. C., Bastian, J., Chung, K. J., Colan, S. D. et al., A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991. 324: 1633-1639.
15. Furukawa, S., Matsubara, T., Jujoh, K., Yone, K., Sugawara, T., Sasai, K., Kato, H. et al., Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin. Immunol. Immunopathol. 1988. 48: 247-251.
16. Matsubara, T., Ichiyama, T. and Furukawa, S., Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin. Exp. Immunol. 2005. 141: 381-387.
17. Hui-Yuen, J. S., Duong, T. T. and Yeung, R. S., TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J. Immunol. 2006. 176: 6294-6301.
18. Burns, J. C., Best, B. M., Mejias, A., Mahony, L., Fixler, D. E., Jafri, H. S., Melish, M. E. et al., Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 2008. 153: 833-838.
19. Franchi, L., Eigenbrod, T., Munoz-Planillo, R. and Nunez, G., The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009. 10: 241-247.
20. Akira, S., Isshiki, H., Sugita, T., Tanabe, O., Kinoshita, S., Nishio, Y., Nakajima, T. et al., A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. Embo. J. 1990. 9: 1897-1906.
21. Dunn, S. M., Coles, L. S., Lang, R. K., Gerondakis, S., Vadas, M. A. and Shannon, M. F., Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 1994. 83: 2469-2479.
22. Hu, H. M., Baer, M., Williams, S. C., Johnson, P. F. and Schwartz, R. C., Redundancy of C/EBP alpha, -beta, and -delta in supporting the lipopolysaccharide-induced transcription of IL-6 and monocyte chemoattractant protein-1. J. Immunol. 1998. 160: 2334-2342.
23. Abe, J., Ebata, R., Jibiki, T., Yasukawa, K., Saito, H. and Terai, M., Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J. Allergy Clin. Immunol. 2008. 122: 1008-1013.
24. Broudy, V. C., Kaushansky, K., Harlan, J. M. and Adamson, J. W., Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J. Immunol. 1987. 139: 464-468.
25. Zsebo, K. M., Yuschenkoff, V. N., Schiffer, S., Chang, D., McCall, E., Dinarello, C. A., Brown, M. A. et al., Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. Blood 1988. 71: 99-103.
26. Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y., Burns, J. C., Shulman, S. T. et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004. 110: 2747-2771.
27. Leung, D. Y., Cotran, R. S., Kurt-Jones, E., Burns, J. C., Newburger, J. W. and Pober, J. S., Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989. 2: 1298-1302.
28. Suzuki, H., Uemura, S., Tone, S., Iizuka, T., Koike, M., Hirayama, K. and Maeda, J., Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur. J. Pediatr. 1996. 155: 291-296.
29. Fury, W., Tremoulet, A. H., Watson, V. E., Best, B. M., Shimizu, C., Hamilton, J., Kanegaye, J. T. et al., Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum. Immunol. 2010. 71: 865-873.
30. Weng, K. P., Hsieh, K. S., Ho, T. Y., Huang, S. H., Lai, C. R., Chiu, Y. T., Huang, S. C. et al., IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ. J. 2010. 74: 544-551.
31. Macmillan, H. F., Rowter, D., Lee, T. and Issekutz, A. C., Intravenous immunoglobulin G selectively inhibits IL-1alpha-induced neutrophil-endothelial cell adhesion. Autoimmunity 2010. 43: 619-627.
32. Xu, C., Poirier, B., Duong Van Huyen, J. P., Lucchiari, N., Michel, O., Chevalier, J. and Kaveri, S., Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am. J. Pathol. 1998. 153: 1257-1266.
33. Matsuda, A., Fukuda, S., Matsumoto, K. and Saito, H., Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am. J. Respir. Cell Mol. Biol. 2008. 38: 168-175.
34. Shimizu, M., Pelisek, J. and Nikol, S., Vasculogenesis and angiogenesis depend on the developmental origin in the arterial tree. Curr. Med. Chem. 2002. 9: 1619-1630.
35. Matsuda, A., Orihara, K., Fukuda, S., Fujinaga, H., Matsumoto, K. and Saito, H., Corticosteroid enhances TNF-alpha-mediated leukocyte adhesion to pulmonary microvascular endothelial cells. Allergy 2008. 63: 1610-1616.
36. Orihara, K. and Matsuda, A., Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: possible implications of tumor necrosis factor-alpha and CXC chemokines. Int. J. Chron. Obstruct. Pulmon. Dis. 2008. 3: 619-627.
37. Futamura, K., Orihara, K., Hashimoto, N., Morita, H., Fukuda, S., Sagara, H., Matsumoto, K. et al., beta2-adrenoceptor agonists enhance cytokine-induced release of thymic stromal lymphopoietin by lung tissue cells. Int. Arch. Allergy Immunol. 2010. 152: 353-361.
38. Yagami, A., Orihara, K., Morita, H., Futamura, K., Hashimoto, N., Matsumoto, K., Saito, H. et al., IL-33 mediates inflammatory responses in human lung tissue cells. J. Immunol. 2010. 185: 5743-5750.
39. Newburger, J. W., Sleeper, L. A., McCrindle, B. W., Minich, L. L., Gersony, W., Vetter, V. L., Atz, A. M. et al., Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 2007. 356: 663-675.
40. Ichiyama, T., Ueno, Y., Isumi, H., Niimi, A., Matsubara, T. and Furukawa, S., An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm. Res. 2004. 53: 253-256.
41. Litvak, V., Ramsey, S. A., Rust, A. G., Zak, D. E., Kennedy, K. A., Lampano, A. E., Nykter, M. et al., Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat. Immunol. 2009. 10: 437-443.